Inspire Medical receives FDA approval for next-gen Inspire V neurostimulation system

Inspire Medical Systems, Inc.

FDA approved Inspire V system including next-generation neurostimulator, Bluetooth patient remote, and physician programmer.
Targets soft launch in late 2024 and full commercial launch in 2025.
Company focusing on operational readiness: product manufacturing and inventory levels for U.S. launch.
CEO cites FDA approval as a key milestone for Inspire therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.